| Typicality: | 0.332 |
| Saliency: | 0.193 |
| intravenously | 4 | manner |
| for treating patients | 4 | purpose |
| without bevacizumab | 4 | other |
| trial → be given with → paclitaxel | 4 |
| trial → be → paclitaxel | 3 |
| trial → compare → paclitaxel | 3 |
| negative | neutral | positive |
| 0.050 | 0.784 | 0.165 |
| Raw frequency | 10 |
| Normalized frequency | 0.193 |
| Modifier score | 0.500 |
| Perplexity | 386.223 |